Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib

World Journal of Urology

Volumn 29, Issue 6, 2011, Pages 807-813

  Riesenbeck, L M ^a   Bierer, S ^a   Hoffmeister, I ^a   Kopke T ^a   Papavassilis, P ^a   Hertle, L ^a   Thielen, B ^a   Herrmann, E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Hypothyroidism; Progression free survival; Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; LIOTHYRONINE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; SORAFENIB; SUNITINIB; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROTROPIN; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 81855163405     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0627-2     Document Type: Article

References (21)

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Target study group sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
4. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23: 832-841.
5. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC (2010) European association of urology guideline group eau guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398-406.
6. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009) NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 7: 618-630.
7. Sternberg CN, Davis ID, Mardiak J, SZczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068.
8. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296.
9. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17: 351-355.
10. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92: 3531-3534.
11. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145: 660-664.
12. Torino F, Corsello SM, Longo R, Barnabai A, Gasparini G (2009) Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? Thyroid 19: 539-540.
13. Surks MI, Hollowell JG (2007) Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 92: 4575-4582.
14. Wolter P, Stefan C, Decallonne B, Dumez H, Fieuws S, Wildiers H, Clement P, Debaere D, van Oosterom A, Schöffski P (2008) Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer(RCC). J Clin Oncol suppl 26: abstract 5126.
15. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99: 448-454.
16. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC (2010) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer (Epub ahead of print).
17. Patel PH, Chadalavada RS, Ishill NM, Patil S, Reuter VE, Motzer RJ, Chaganti RS (2008) Hypoxia-inducible factor (HIF)1a and 2a levels in cell linies and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol suppl 26: abstract 5008.
18. Hutson TE, Davis ID, Machiels JH, de Souza PL, Baker K, Bordogna W, Westlund R, Crofts T, Pandite L, Figlin RA (2008) Biomarker analysis and final efficacy results of a phase II renal cell carcinoma trial with pazopanib(GW786034). J Clin Oncol suppl 26: abstract 5046.
19. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH (2009) Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9: 82.
20. Han KS, Jung DC, Choi HJ, Jeong MS, Cho KS, Joung JY, Seo HK, Lee KH, Chung J (2010) Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 116: 2332-2342.
21. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Ricart AD, Olszanski AJ, Kim S, Spano J (2008) Association of diastolic blood pressure (dBP) & 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). J Clin Oncol suppl 26: abstract 3543.